Navigation Links
Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
Date:6/27/2011

markets;
  • The global partnership will include equal management representation from Verenium and Novus to direct various activities, including budgeting, development and marketing plans;
  • The companies will partner equally to fund development and commercialization and share in the profits, as well as provide other resources and expertise that would otherwise have been funded solely by Verenium;
  • Verenium will receive license payments of $2.5 million upon signing and $2.5 million following regulatory filings or commercial activity; and
  • In the marketplace, all products will be co-branded by Verenium and Novus.

  • About The Animal Health and Nutrition MarketEnzymes are used in the animal health and nutrition market to allow livestock, poultry, aquaculture and companion animals to more readily digest and absorb the nutrients naturally occurring in grains and protein meals.  According to industry reports in the animal health and nutrition market, enzymes are experiencing remarkable growth due to their ability to provide better nutrition and an improved environmental impact.  Global sales of animal feed enzymes are estimated to have reached $520 million in 2010, and are expected to grow 6 to 7 percent annually to reach over $720 million by 2015, making it one of the largest and fastest growing markets for industrial enzymes.  Given the trends of global population growth, increased meat consumption in emerging markets and increased grain prices leading to higher feed costs for producers, enzymes are an effective means of improving the sustainability of animal production both economically and environmentally.

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel market
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
    (Date:11/15/2014)... MA (PRWEB) November 13, 2014 Collaborative ... announced they were named one of the Boston Globe’s ... the Medium Sized Businesses in Massachusetts to receive the ... honors employers who take care of their most valuable ... awards are presented annually, and are based on an ...
    (Date:11/15/2014)... The International Society for Cardiovascular ... society’s Governing Board has grown with the additions ... officer and Dr. Charles Simonton, divisional vice president, ... Mr. Rowe and Dr. Simonton are both medical ... , Dr. Nabil Dib, ISCTR President stated, “We ...
    (Date:11/15/2014)... November 14, 2014 The "Operating ... Surgical, Performance), by Application (Perioperative, Preoperative, operating room ... (Web-Based, On-Premise) - Global Forecast to 2019.” defines ... an analysis and forecast of value by product, ... Along with this, the value and volumes of ...
    Breaking Biology Technology:Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4
    ... WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... the year and quarter ended December 31, 2007. All ... Net loss for the year ended December 31, ... share, compared with $36.4 million, or $2.38,per basic and ...
    ... (Nasdaq: MNKD ) today issued the following ... is absolutely committed to the continued development of ... small,patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin to,patients ... closely matches the pattern,of insulin secretion seen in ...
    ... - Dr. Brad Thompson, President,and CEO of Oncolytics ... a,corporate overview of the Company at the BioSquare ... is being held at the Congress Center in,Basel, ... Biotech Inc., Oncolytics is a Calgary-based biotechnology ...
    Cached Biology Technology:Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008 2
    (Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
    (Date:11/4/2014)... Lithuania , Nov. 4, 2014   ... technologies, today announced that the latest version of ... in the Ongoing MINEX evaluation organized ... of fingerprint algorithms using the INCITS 378 fingerprint ... mandatory requirement in public tenders in ...
    (Date:11/3/2014)... University of Colorado Cancer Center study published ... of Sciences describes the activity of a recently ... 37 or IL-37. It has been known to limit ... the adaptive immune system: IL-37 inhibits the ability of ... , "Knowing this mechanism that underlies IL-37,s effect on ...
    Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
    ... Vegas, NVCONRAD, a leading reproductive health research organization, will announce ... at the Reproductive Health 2011 Conference in Las Vegas, Nevada. ... implemented at six clinical sites in the U.S. showed that ... similar to traditional diaphragms. In addition, SILCS was ...
    ... -- Decreasing expression of a protein associated with susceptibility ... while improving their hormonal response to stress, a study ... found. The lack of this protein, FKBP51, did not ... The study suggests that drug discovery efforts aimed ...
    ... MD The Federation of American Societies for Experimental ... client, the Histochemical Society (HCS). The executive leadership ... include general management support, membership marketing, recruitment, and retention, ... Executive Director of HCS, William Stahl, PhD commented, "HCS ...
    Cached Biology News:CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011 2CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011 3Lack of protein FKBP51 in old mice improves resilience to depressive behavior 2
    ...
    ... Anti-HMGN2/HMG-17 Immunogen : ... Tris-glycine, pH7.4, 5mg/ml BSA, 0.15M ... the addition of glycerol to ... by immunoblot on acid extracts ...
    ...
    ... different human fetal normal tissues are ... upon request. Customers can choose ... set, and pay 70% of the ... P Set products are for research ...
    Biology Products: